- Home
- NWFL vs CTNM Comparison
NWFL vs CTNM Comparison
Compare NWFL & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | NWFL | CTNM |
|---|---|---|
| Founded | 1870 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 273.0M | 507.0M |
| IPO Year | 1996 | 2024 |
Fundamental Metrics
Financial Performance| Metric | NWFL | CTNM |
|---|---|---|
| Price | $28.39 | $12.30 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $33.00 | $19.00 |
| AVG Volume (30 Days) | 14.3K | ★ 241.9K |
| Earning Date | 04-16-2026 | 03-05-2026 |
| Dividend Yield | ★ 4.47% | N/A |
| EPS Growth | ★ 15150.00 | 0.46 |
| EPS | ★ 3.01 | N/A |
| Revenue | ★ $7,999,000.00 | N/A |
| Revenue This Year | $34.35 | N/A |
| Revenue Next Year | $5.55 | N/A |
| P/E Ratio | $9.47 | ★ N/A |
| Revenue Growth | ★ 8.11 | N/A |
| 52 Week Low | $21.25 | $3.35 |
| 52 Week High | $32.23 | $16.33 |
Technical Indicators
Market Signals| Indicator | NWFL | CTNM |
|---|---|---|
| Relative Strength Index (RSI) | 42.40 | 38.91 |
| Support Level | $27.50 | $10.39 |
| Resistance Level | $29.58 | $13.18 |
| Average True Range (ATR) | 0.86 | 1.18 |
| MACD | -0.08 | -0.30 |
| Stochastic Oscillator | 29.32 | 13.98 |
Price Performance
Historical ComparisonAbout NWFL Norwood Financial Corp.
Norwood Financial Corp is a U.S.-based bank holding company. It offers various personal and business credit services, trust and investment products, and real estate settlement services to consumers, businesses, nonprofit organizations, and municipalities in each of the communities that the bank serves. The bank also manages automated teller machines at its branch location. It serves the Pennsylvanian counties of Wayne, Pike, Monroe, and Lackawanna, as well as Susquehanna County.
About CTNM Contineum Therapeutics Inc.
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.